Enrollment open • Trial initiation date • Combination therapy
|
HLA-A (Major Histocompatibility Complex, Class I, A) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression
|
Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)